BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 32504035)

  • 1. Molecular characterization of diffuse malignant peritoneal mesothelioma.
    Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
    Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
    Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
    Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
    Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
    J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of localized pleural mesothelioma.
    Hung YP; Dong F; Dubuc AM; Dal Cin P; Bueno R; Chirieac LR
    Mod Pathol; 2020 Feb; 33(2):271-280. PubMed ID: 31371807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
    Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
    Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
    Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
    JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
    Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
    Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
    Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features.
    Michal M; Kravtsov O; Ross JS; Skanderová D; Martínek P; Mosaieby E; Mata DA; Williams EA; Hung YP
    Genes Chromosomes Cancer; 2023 May; 62(5):267-274. PubMed ID: 36515470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Characterization of Peritoneal Mesotheliomas.
    Offin M; Yang SR; Egger J; Jayakumaran G; Spencer RS; Lopardo J; Nash GM; Cercek A; Travis WD; Kris MG; Ladanyi M; Sauter JL; Zauderer MG
    J Thorac Oncol; 2022 Mar; 17(3):455-460. PubMed ID: 34648949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42.
    Stevers M; Rabban JT; Garg K; Van Ziffle J; Onodera C; Grenert JP; Yeh I; Bastian BC; Zaloudek C; Solomon DA
    Mod Pathol; 2019 Jan; 32(1):88-99. PubMed ID: 30171198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
    Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S
    Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
    Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
    J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant.
    Shinozaki-Ushiku A; Kohsaka S; Kage H; Oda K; Miyagawa K; Nakajima J; Aburatani H; Mano H; Ushiku T
    Pathol Int; 2020 Oct; 70(10):775-780. PubMed ID: 32583627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of
    Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
    Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma.
    Schaefer IM; Mariño-Enríquez A; Hammer MM; Padera RF; Sholl LM
    Mod Pathol; 2023 Sep; 36(9):100237. PubMed ID: 37295554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic landscape of pleural and peritoneal mesothelioma tumours.
    Hiltbrunner S; Fleischmann Z; Sokol ES; Zoche M; Felley-Bosco E; Curioni-Fontecedro A
    Br J Cancer; 2022 Nov; 127(11):1997-2005. PubMed ID: 36138075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years.
    Vitlarov N; Burtscher E; Pfeiffenberger E; Wahl A; Hodja V; Jasarevic Z; Kashofer K; Offner FA
    Virchows Arch; 2023 Dec; 483(6):873-878. PubMed ID: 37428268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
    Hung YP; Chirieac LR
    Arch Pathol Lab Med; 2024 May; 148(5):e77-e89. PubMed ID: 38190277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.
    Shrestha R; Nabavi N; Lin YY; Mo F; Anderson S; Volik S; Adomat HH; Lin D; Xue H; Dong X; Shukin R; Bell RH; McConeghy B; Haegert A; Brahmbhatt S; Li E; Oo HZ; Hurtado-Coll A; Fazli L; Zhou J; McConnell Y; McCart A; Lowy A; Morin GB; Chen T; Daugaard M; Sahinalp SC; Hach F; Le Bihan S; Gleave ME; Wang Y; Churg A; Collins CC
    Genome Med; 2019 Feb; 11(1):8. PubMed ID: 30777124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.